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Background: Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. The present
treatment including surgery, chemotherapy and radiation, which have only 40% long-term cure rates, and usually
cause tumor recurrence. Thus, looking for new effective and less toxic therapies has important significance. XAV939
is a small molecule inhibitor of tankyrase 1(TNKS1). The objective of this study is to investigate the effect of XAV939
on the proliferation and apoptosis of NB cell lines, and the related mechanism.
Methods: In the present study, we used both XAV939 treatment and RNAi method to demonstrate that TNKS1
inhibition may be a potential mechanism to cure NB. MTT method was used for determining the cell viability and
the appropriate concerntration for follow-up assays. The colony formation assay, Annexin V staining and cell cycle
analysis were used for detecting colony forming ability, cell apoptosis and the percentage of different cell cycle.
The Western blot was used for detecting the expression of key proteins of Wnt/ beta-catenin (Wnt/β-catenin)
signaling pathway.
Results: The results showed that TNKS1 inhibition decreased the viability of SH-SY5Y, SK-N-SH and IMR-32 cells,
induced apoptosis in SH-SY5Y as well as SK-N-SH cells, and led to the accumulation of NB cells in the S and G2/M
phase of the cell cycle. Moreover, we demonstrated TNKS1 inhibition may in part blocked Wnt/β-catenin signaling
and reduced the expression of anti-apoptosis protein. Finally, we also demonstrated that TNKS1 inhibition
decreased colony formation in vitro.
Conclusions: These findings suggested that TNKS1 may be a potential molecule target for the treatment of NB.
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Neuroblastoma (NB) is the most common extracranial
solid tumor in childhood and infancy, which is an embry-
onic tumor of the postganglionic sympathetic nervous sys-
tem. It remains an important pediatric problem because it
accounts for 8–10% of all childhood cancers and for ap-
proximately 15% of cancer deaths in children [1-3]. It is as-
sociated with poor prognosis because of its ability to
regress spontaneously, transform, or show aggressive be-
havior [4]. Current treatment for high-risk NB consists of
a coordinated sequence of chemotherapy, surgery, and* Correspondence: shuling_bai@126.com
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reproduction in any medium, provided the orradiation [5,6]. Even with this aggressive treatment, less
than 40% of children are likely to achieve long-term cure
[5-7]. After that the patients usually underwent tumor re-
currence as well as long-term complications following
high-dose chemotherapy [8,9]. There is an urgent need for
more effective and less toxic therapies, and molecular
target-directed drugs are potential representation.
The evolutionarily conserved Wnt/beta-catenin (Wnt/
β-catenin) pathway, which is well-described and canon-
ical, is related to human birth defects, cancer, and other
diseases [10]. Wnt signal pathway is one of the fundamen-
tal mechanisms that regulate cell proliferation, cell polarity
and cell differentiation during embryonic development
[11]. As a result, inappropriate regulation of Wnt signaling
occurs in several types of cancer, including colon, liver and. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Wnt/β-catenin pathway is activated or not depends on the
stability of β-catenin in the cytoplasm. β-catenin is
regulated by a destruction complex, which is composed of
the scaffolding protein Axin, the tumor suppressor aden-
omatous polyposis coli gene product (APC), casein kinase
1, and glycogen synthase kinase 3(GSK3). In the absence
of Wnt stimulation, β-catenin is phosphorylated by the
complex and degraded by the ubiquitination/proteasome
pathway. In the presence of Wnt, the Axin-mediated
β-catenin phosphorylation can be inhibited, then, accumu-
lated β-catenin enters the nucleus and binds to the
TCF/LEF family of DNA-binding factors for activation of
Wnt pathway-responsive gene transcription, such as cyclin
D1, c-myc, axin2 and so on [10,12]. Inhibition of Wnt
signaling has become an attractive strategy for cancer
therapeutics [13].
An exciting study published recently in Nature [14], to-
gether with an earlier one [15], has verified a new class of
small molecule inhibitors, XAV939, which could block Wnt
signaling in colon cancer cell lines by binding to tankyrase
(TNKS) catalytic poly-ADP-ribose polymerase (PARP) do-
main, and then resulted in dramatic stabilization of the
Axin protein, thereby lead to increased β-catenin destruc-
tion. As a major member of the TNKS family, it has been
reported that tankyrase 1(TNKS1) were up-regulated in a
variety of cancers, including multiple myeloma, plasma cell
leukemia, high-grade non-Hodgkin’s lymphomas, breast
cancer, colon cancer, and bladder cancer [16-22]. These
reports suggested that TNKS1 played a role in tumor pro-
gression. Recently, Bao R et al. demonstrated that XAV939
or siRNA-mediated abrogation of TNKS expression in-
creases Axin1 and Axin2 protein levels and attenuates
Wnt-induced transcriptional responses in several breast
cancer lines [23]. In our previous studies, we have
known that TNKS1 was also up-regulated in NB SH-
SY5Y cells (data not shown). It has also been reported
that the β-catenin has a close relationship with the prog-
nosis of NB. The stronger the β-catenin expressed in nu-
cleus, the higher risk of NB would be, and the worse the
prognosis was [24]. However, whether the proliferation of
NB cell lines could be inhibited through blocking the Wnt
pathway or other mechanisms?
In the present study, we have investigated the anti-
proliferative effect of XAV939 on the human NB cell
lines. In addition, we studied the cell apoptosis induced
by XAV939 and assessed the role of Wnt signaling in it.
Materials and methods
Cell culture and TNKS1 inhibitor
Human NB SH-SY5Y, SK-N-SH and IMR-32 cells were
obtained from the American Type Culture Collection
(ATCC; Rockville, USA). Cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Hyclone),with 10% fetal bovine serum (FBS; Gibco) and 1%
penicillin/streptomycin (Sigma Chemical Co., St Louis,
Missouri) and were grown in a 5% CO2 incubator at
37°C. The TNKS1 inhibitor XAV939 was purchased from
Sigma Aldrich.
Assessment of cellular viability
Cellular viability was assessed by MTT method. Briefly,
equal numbers of NB SH-SY5Y, SK-N-SH and IMR-32
cells were plated at a density of 1 × 104 per well in 96-
well plates, and were treated with various concentrations
of XAV939 for 24, 48, or 72 h. 20 μl MTT (5 mg/ml)
were incubated with cells of each sample for 4 h, then
were replaced with 150 μl DMSO and 96-well plates
were rotated gently for 10 min. Cell viability was deter-
mined by measuring colorimetric absorbance at 490 nm,
and was read with a microplate reader [25]. Experiments
were done in triplicate and average activity rates relative
to control and standard errors were calculated.
Colony formation assay
Colony formation assays were performed as described
[26]. Briefly, SH-SY5Y cells were plated in triplicate at 100
cells per well in 6-well plates and cultured in DMEM
medium supplemented with 10% FBS. After 4-5 h, cells
were treated with DMSO or XAV939, as well as trans-
fected with lentivirus-mediated scrambled-shRNA (SCR
group) or TNKS1-shRNA (shRNA group). Colonies were
allowed to form for 14 days and fixed in methanol for
15 minutes, and dyed with crystal violet for 15 minutes at
room temperature. Afterward, the dye was washed off and
colonies that contained more than 50 cells were counted.
The colony formation efficiency was the ratio of the col-
ony number to the planted cell number.
Apoptosis assays
Apoptosis was measured using Annexin V/FITC Apop-
tosis Detection kit (KeyGEN Biotech, Nanjing, China)
following the manufacturer’s protocol. Briefly, equal num-
bers of SH-SY5Y and SK-N-SH cells, treated with DMSO
or XAV939 for 24, 48, or 72 h, were incubated with
Annexin V-FITC, followed by staining of their DNA with
propidium iodide (PI) in the dark. Then, each sample was
analyzed by fluorescence-activated cell sorting (FACS)
(BD, San Jose, CA, USA). The percentages of cells staining
positive for Annexin V were calculated, and means as
well as standard error were plotted. Alternatively, apop-
tosis was also determined using Hoechst 33342 staining.
After treatment, cells were washed with PBS and stained
with Hoechst 33342 (10 μg/mL, Sigma Aldrich). Then the
cells were observed by fluorescent microscope (Olympus
Inverted Fluorescence Microscope, I × 71) with excitation
at 340 nm and approximately 100 cells from five ran-
dom microscopic fields were counted. The percentage of
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to total cells. Mean and standard error were calculated for
each time point and treatment group.
Cell cycle analysis
Equal numbers of SH-SY5Y, SK-N-SH and IMR-32 cells
were plated in 10 cm dishes and treated with DMSO or
XAV939 for 24, 48, or 72 h. 106 cells were trypsinized,
fixed with 70% ethanol, and incubated over night at 4°C,
then were incubated in 100 μl RNase at 37°C for 30 min,
followed by staining of their DNA with 400 μl PI for
30 min in the dark, and analyzed by FACS. The average
percentages of cells in G0/G1, S or G2/M phases of the
cell cycle were quantified and standard error was calcu-
lated for three experiments.
Western blot
Equal numbers of SH-SY5Y and SK-N-SH cells were
plated on 10 cm dishes and treated with DMSO or
XAV939 for 24, 48 or 72 h. Then the cells were lysed with
RIPA buffer and protein concentration was determined by
the Bradford method. Equal amounts of protein (40 μg)
were used for Western blot analysis with antibodies to
anti-β-catenin (Santa Cruz, sc-7199), anti-Cyclin D1
(Santa Cruz, sc-718), anti-c-Myc (Santa Cruz: sc-789) and
anti-Bcl-2 (Santa Cruz, sc-492). Specific antibody binding
was detected by horseradish peroxidase-conjugated goat
anti-rabbit antibodies and visualized with ECL reagent
(Santa cruz) according to the manufacturer’s protocol.
Antibody to actin was used to evaluate protein loading in
each lane.
Silencing of TNKS1 with shRNA
To identify shRNA sequences could knockdown TNKS1
in SH-SY5Y and SK-N-SH cells, we screened three MIS-
SION shRNA clones NM_003747 (GENECHEM CO.,
LTD., Shanghai, China) targeted against the human
TNKS1 sequence. MISSION shRNA clones together with
packaging and envelope plasmids GV118 (GENECHEM
CO., LTD., Shanghai, China), were transfected into HEK
293 T packaging cells using Lipofectamine 2000 (Invitro-
gen). At 48 h post-transfection, virus-containing media
was used to infect NB cell lines. GFP was used to monitor
the efficiency of HEK 293 T transfection and infection.
After selection with puromycin (5 μg/ml) for 48 h, cells
were tested for TNKS1 expression by qRT-PCR and
then used for clonogenic survival assays and Western
blot analyses.
Statistical analysis
The results were presented as Mean ± Standard devi-
ation (S.D.) of triplicate determinations. The data were
processed using the Statistical Package for the Social
Sciences, version 16.0 (SPSS Inc., Chicago, IL, USA).One-way ANOVA was performed for comparison be-
tween different groups. Dunnett’s t (when homogeneity
of variances existed) or Dunnett T3 (when heterogeneity
of variances existed) was calculated. A P-value of < 0.05
was regarded as statistically significant difference.
Results
TNKS1 inhibition decreases cell growth and proliferation
in NB cell lines
XAV939 has been described as a potent, small molecule
inhibitor of TNKS1 and 2 and could inhibit the growth
of DLD-1 cancer cells [14]. To elucidate the role of
XAV939 in NB, we investigated how XAV939 affects cell
proliferation in NB cell lines with different concentra-
tions. After that, both SH-SY5Y cells and IMR-32 cells
showed reduction in cell proliferation after 24 h of treat-
ment with 1 μM XAV939, with a maximum reduction
at 72 h (Figure 1A, B). However, SK-N-SH cells showed
the same effect only with 0.5 μM XAV939 treatment
(Figure 1C). This anti-proliferative effect was dose and
time dependent at 1, 5, 10 and 50 μM at 24, 48 and
72 h. These results indicate that inhibition of TNKS1 by
small molecule inhibitor attenuates NB cell proliferation.
Thus 1 or 0.5 μM XAV939 were used depending on the
cell lines for further assays.
TNKS1 inhibition reduces SH-SY5Y cell survival
To determine whether TNKS1 inhibition reduces cell via-
bility and survival of SH-SY5Y cells, we performed a col-
ony formation assay in vitro. The number of colonies in
the control and various treatment groups were counted
and are summarized in Figure 2. From these results it is
evident that the XAV939 caused 62.7% inhibition of col-
ony formation in SH-SY5Y cells. In addition, we also ob-
served the effect of shRNA for TNKS1 on cell colony
formation. As shown in Figure 2, specific knockdown of
TNKS1 by shRNA in SH-SY5Y cells resulted in a signifi-
cant decrease (55.3%) in the number of colonies, as com-
pared to SCR group (P < 0.01, Figure 2B). These results
indicate that the growth inhibitory effects of XAV939 on
SH-SY5Y cells are due to TNKS1-dependent inhibition.
TNKS1 inhibition induces apoptosis in NB cell lines
Apoptosis plays an important role in both the cause
and treatment of tumor [27]. The early apoptotic cells
could be stainned by Annexin V, which located in the
right lower quadrant (Figure 3A, E). Both the SH-SY5Y
and SK-N-SH cell lines showed that no significant dif-
ference in the percentage of apoptotic cells between the
control and XAV939 group for 24 h (Figure 3B, G).
However, after 48 h or 72 h treatment, the apoptotic
rates in XAV939 group were 3.31 ± 0.17% and 5.41 ±
0.63% respectively in SH-SY5Y cells (Figure 3B), which
were significantly higher than those in control group
Figure 1 The cellular activity of SH-SY5Y, SK-N-SH and IMR-32
cells after XAV939 treatment at 24 h, 48 h and 72 h. A. The
cellular activity of SH-SY5Y cells. B. The cellular activity of IMR-32
cells. C. The cellular activity of SK-N-SH cells. P < 0.05.
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XAV939 group were 3.69 ± 0.31% and 5.44 ± 0.24% re-
spectively in SK-N-SH cells (Figure 3G, P < 0.05). To
further confirm that TNKS1 inhibition induced apop-
tosis in NB cell lines, we studied the nuclear morphology
of SH-SY5Y and SK-N-SH cells following Hoechst 33342
staining (Figure 3C, F). As depicted in Figure 3C and F,control cells without XAV939 treatment were uniformly
stained with and displayed equally disseminated chroma-
tin, normal and intact cell membrane. In contrast, cells
treated with XAV939 for 24, 48, or 72 h illustrated vary-
ing degrees of archetypal characteristics of apoptotic
cells, including the condensation of chromatin, shrinkage
of nuclei, and presence of apoptotic bodies with intense
blue fluorescence (Figure 3C, F). The major findings were
showed by arrows in Figure 3C, F. In SH-SY5Y cells, the
percentages of cells with apoptotic nuclei in XAV939
group were 9.2%, 25.0% and 52.3% respectively at 24 h, 48
h and 72 h, which in control group were 8.8%, 13.8% and
15.0% respectively (Figure 3D). In SK-N-SH cells, The per-
centages of cells with apoptotic nuclei in XAV939 group
were 5.7%, 35.5% and 53.5% respectively at 24 h, 48 h and
72 h, which in control group were 4.5%, 13.2% and 13.5%
respectively (Figure 3H). The statistical analysis showed
that there was no significant difference of apoptotic cells
between the control and XAV939 groups at 24 h, but the
percentages of apoptotic cells in XAV939 group were sig-
nificant higher than those in control group at 48 h and 72
h respectively (P < 0.05, Figure 3D, H), confirming the in-
duction of apoptosis following treatment. Together, these
results suggest that apoptosis is promoted by TNKS1 in-
hibition in NB cell lines.
TNKS1 inhibition induces the accumulation of NB cell
lines at G2/M
TNKS1 was proposed to be required for the resolution
of sister telomere association or assembly of bipolar
spindles, and TNKS1 knockdown was reported to cause
strong mitotic arrest [28,29]. We detected the effect of
XAV939 on cell cycle in SH-SY5Y, SK-N-SH and IMR-
32 cells. As shown in Figure 4A, the number of SH-
SY5Y cells in the G0/G1 phase decreased, while those in
the S and G2/M phase both increased after XAV939
treatment (Figure 4A). At 24 h after treatment, 58.25%
of the DMSO-treated SH-SY5Y cells were at G0/G1,
28.02% at S and 13.73% at G2/M (Figure 4B, P < 0.05).
In comparison, 48.38% of the XAV939-treated SH-SY5Y
cells were at G0/G1, 33.68% at S and 17.94% at G2/M
(Figure 4B, P < 0.05). This trend was continued at later
time points (Figure 4B). Figure 4C, E indicated the cell
cycle of SK-N-SH and IMR-32 cells respectively, and
showed the same tendency with that of SH-SY5Y cells
(Figure 4D, F, P < 0.05). This suggested that TNKS1 plays
a role in cell cycle regulation and that TNKS1 inhibition
induces an accumulation of NB cell lines at G2/M and S
phase of the cell cycle.
TNKS1 inhibition reduces the expression of anti-apoptotic
proteins
It has been reported that XAV939 could inhibit the pro-
liferation of DLD-1 cells growth by attenuating the
Figure 2 TNKS1 inhibition induces cell death in SH-SY5Y cells. A. The cell colony stained by 1% crystal violet in control gorup, XAV939
group, SCR group and shRNA group. B. The bar graph depicts the colony forming units(cfu) in different groups. *P < 0.01 compared to controls.
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performed to determine if TNKS1 inhibition induces
apoptosis in SH-SY5Y and SK-N-SH cells and if so
whether Wnt/β-catenin signalling and Bcl-2 plays a
role. TNKS1 in SH-SY5Y and SK-N-SH cells was inhib-
ited by XAV939 of 1 and 0.5 μM, or by specific shRNA
to TNKS1. Following inhibition of TNKS1 in SH-SY5Y
and SK-N-SH cells, protein levels of Bcl-2 were both
reduced (P < 0.05, Figure 5A, B; P < 0.01, Figure 5C, D).
This suggests that TNKS1 inhibition might induce apop-
tosis in NB cell lines in part by reducing expression of the
anti-apoptotic protein Bcl-2. After treating with XAV939
or specific shRNA to TNKS1, we noted that the accumu-
lation of β-catenin reduced as well as Cyclin D1 and
c-Myc in both NB cell lines (Figure 5A, C). Quantification
analysis revealed these results (P < 0.05, Figure 5B, D). As
a result, the anti-apoptotic protein Bcl-2 also decreased.
Discussion
NB is the most common malignancy of infancy and con-
stitutes 50% of all infantile cancers. NB with higher-
grade are quite aggressive and have low cure rates even
with combined modality treatments of surgery, radiation
and chemotherapy [30]. Understanding the molecular
mechanism of NB could help us find key targets which
could be exploited efficiently for therapy.
TNKS is a member of the PARP family, which uses
NAD + as a substrate to generate ADP-ribose polymers
onto target proteins, and results in a post-translational
modification referred to as PARsylation [31]. TNKS1
was previously identified as a binding partner fortelomerase repeat binding factor 1 (TRF1), which is an
important player in the regulation of telomere length at
the chromosome ends. It has been shown that TNKS1
expression is up-regulated in several human cancers,
and correlates significantly with highly aggressive disease
and poor prognosis in some types of cancer, such as
breast, colon, and bladder cancer [19-21]. Thus, TNKS1
could be potential therapeutic target for the treatment of
malignant NB that overexpressing TNKS1. XAV939, a
TNKS1 inhibitor, is synthetized using a chemical genet-
ics approach, and reported to have been used against
cancers like colorectal cancers [14,15] and WTK1 hu-
man lymphoblastoid cells [32]. However, the antagonism
of XAV939 has not been well studied in NB. In the
present study we show that inhibition of TNKS1 either
by small molecule inhibitor XAV939 or by a specific
shRNA decreases the cell viability of NB cell lines
(Figure 1). This phenomenon can be explained by induc-
tion of apoptosis (Figure 3) or cell cycle arrest (Figure 4).
Furthermore, we assessed the effects of TNKS1 inhib-
ition on cell survival and proliferation in SH-SY5Y and
SK-N-SH cells. It has been reported that inhibition of
TNKS1 leading to decreased levels of β-catenin by sta-
bilizing Axin and turning off Wnt/β-catenin signaling
[14,33]. We showed that SH-SY5Y cells treated with
XAV939 induces disaggregation of β-catenin compared
to untreated controls (Figure 5), indicating that TNKS1
inhibition leads to degradation of β-catenin. We also
found that the downstream target proteins of β-catenin,
such as Cyclin D1 and c-Myc, were down-regulated,
which demonstrated that Wnt/β-catenin signaling was
Figure 3 TNKS1 inhibition induces cell apoptosis in SH-SY5Y and SK-N-SH cells. A, E. The figures of SH-SY5Y and SK-N-SH cells stained with
Annexin V in control group and XAV939 group. B, G. The bar graph of average percent of apoptotic cells in control group and XAV939 group.
*P < 0.05 compared to controls. C, F. The morphology of apoptotic nuclei was observed by Hoechst 33342 staining. The arrows point at the
apoptotic nuclei. D, H. The bar graph of percentages of apoptotic cells in control group and XAV939 group. *P < 0.05 compared to controls.
The apoptosis of SH-SY5Y cells was indicated by figures A, B, C and D, while that of SK-N-SH cells was indicated by figures E, F, G and H.
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Figure 4 TNKS1 inhibition induces G2/M accumulation in SH-SY5Y, SK-N-SH and IMR-32 cells. A, C, E. The representative diagrams of
distribution of stained SH-SY5Y, SK-N-SH and IMR-32 cells in control group and XAV939 group. B, D, F. The bar graph of the average percent cells
of G0/G1, S and G2/M phases in control group and XAV939 group for SH-SY5Y, SK-N-SH and IMR-32 cells respectively (P < 0.05).
Figure 5 TNKS1 inhibition altered the expression of anti-apoptotic proteins. A, C. Western blot analysis of β-catenin, Cyclin D1, c-Myc and
Bcl-2 proteins level in SH-SY5Y and SK-N-SH cells untransfected, XAV939 treatment, transfected with TNKS1 shRNA or control shRNA. β-actin was
loading control. B, D. The bar graph showed mean ± SD of the ratio interest proteins/β-actin band intensity obtained by pooling the results from
3 independent experiments in SH-SY5Y and SK-N-SH cells respectively. CON: control group; XAV: XAV939 group; SCR: SCR group; shRNA: RNAi
TNKS1 group. *P < 0.05, **P < 0.01 compared to controls.
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able to drive cell proliferation during tumor formation
by turning on the cell-cycle regulator Cyclin D1 [34],
and c-Myc serves as important role in prognosis of NB
[35]. The Bcl-2 family of proteins plays a key role in
regulation of mitochondrial permeability during apop-
tosis via intrinsic pathway. In our present study we
showed that inhibition of TNKS1 with XAV939 reduced
Bcl-2 proteins in SH-SY5Y cancer cells (Figure 5) con-
sistent with the promotion of apoptosis.
Moreover, TNKS1 has been shown to regulate sister
telomere separation [36] and mitotic progression [29].
However, there are some glaring discrepancies between
the results of Huang et al. and earlier studies on TNKS1
function during mitosis. Huang et al. found that small
molecule drug XAV939 didn’t cause mitotic arrest in
DLD-1 colon cancer cells, neither RNAi-TNKS1 do. The
results were in sharp contrast with other studies
[28,29,31]. In the present study we also found that the
three NB cell lines, when treated with XAV939, have a
prolonged S phase followed by a G2/M cell cycle arrest
compared to untreated cells. This discrepancy may be
related to different types of cancer and need to be fur-
ther investigated.
Recently it has been shown that XAV939 inhibits DLD-
1 colony formation in an axin-dependent manner [14].
Axin is a concentration-limiting factor in the β-catenin
degradation complex and may function more generally as
a signal ‘integrator’ in modulating Wnt pathway activity.
In our studies, XAV939 as well as shRNA for TNKS1
inhibited SH-SY5Y colony formation in vitro (Figure 2). In
conclusion, the present data and previous studies indicate
that small molecule inhibitors XAV939 could inhibit the
proliferation and colony formation of SH-SY5Y cells by
inhibiting TNKS1 might in part through Wnt/β-catenin
signaling. But the results are required to be validated
in vivo to get a better understanding of the mechanisms
involved and the potential role of XAV939 in NB treat-
ment. Moreover, TNKS1 is a protein that participates in
both telomere regulation and Wnt/β-catenin signaling,
which are essential factors for tumor remedy and recur-
rence. However, the relationship between the telomere
regulation and Wnt/β-catenin signaling need to be further
explored. The research will pave the way for NB treatment
used by TNKS1 inhibitors.Conclusions
In sum, we have shown that inhibition of TNKS1 by
XAV939 or RNAi method inhibits the proliferation and
induces apoptosis of NB cell lines. One of the related
mechanisms may be the inhibiting of Wnt/β-catenin sig-
naling. But more experiments should be carried out to
clarify the exact mechanisms. This effect would beexpected to promote small molecule targeted therapy in
patients with malignant NB.
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